Zhongsheng Pharmaceutical (01177) is now down more than 5%. As of press release, it is down 5.4% to HK$2.98, with a turnover of HK$87.326 million.
The Zhitong Finance App learned that Zhongsheng Pharmaceutical (01177) is now down more than 5%. As of press release, it is down 5.4% to HK$2.98, with a turnover of HK$87.326 million.
According to the news, Citi published a report stating that it kept its revenue forecast for Zhongsheng Pharmaceuticals unchanged, but due to the offset of minority shareholders' equity percentage, it lowered its earnings forecast per share. The target price was lowered from HK$9 to HK$7.4, maintaining the “buy” rating.
HSBC previously pointed out that most of the company's negative factors have been reflected in the stock price. Considering the company's low vaccine inventory level, it is estimated that the impact of impairment will be limited, and it remains optimistic about its growth prospects. The bank believes that the growth prospects for Zhongsheng Pharmaceutical are stable. The current price level is 15 times the price-earnings ratio in 2024, which is 19 times lower than the industry average. The valuation is attractive. It maintains a “buy” rating, and reduces the target price from HK$5 to HK$4.6 in response to the latest valuation.